Teleflex Completes Enrollment in Percutaneous Coronary Intervention Study
Teleflex Incorporated, a leading global provider of medical technologies, has announced the successful completion of patient enrollment in the RingerTM PTCA study. This groundbreaking study is one of two clinical trials that aim to evaluate the performance and effectiveness of the innovative RingerTM Perfusion Balloon Catheter. The study was conducted at seven prestigious complex PCI centers located in both the United States and Canada, under the leadership of Principal Investigator Kathleen Kearney M.D. from the esteemed University of Washington.
The primary focus of the RingerTM PTCA study was to identify patients who could potentially benefit from continuous perfusion during coronary balloon inflations. With the completion of patient enrollment, this important milestone brings us closer to obtaining valuable clinical validation and regulatory approval for Teleflex's release of the revolutionary RingerTM Perfusion Balloon Catheter as a viable treatment option for eligible patients.
&